Further opti'/>
机译:Fevipiprant(NVP-QAW039)的发现,有效和选择性DP 2 sub>受体拮抗剂用于治疗哮喘
Novartis Institutes for Biomedical Research Horsham Research Centre Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom;
Novartis Institutes for Biomedical Research Horsham Research Centre Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom;
Novartis Institutes for Biomedical Research Horsham Research Centre Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom;
Novartis Institutes for Biomedical Research Horsham Research Centre Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom;
Novartis Institutes for Biomedical Research Horsham Research Centre Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom;
Novartis Institutes for Biomedical Research Horsham Research Centre Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom;
Novartis Institutes for Biomedical Research Horsham Research Centre Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom;
Novartis Institutes for Biomedical Research Horsham Research Centre Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom;
Novartis Institutes for Biomedical Research Horsham Research Centre Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom;
Novartis Institutes for Biomedical Research Horsham Research Centre Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom;
Novartis Institutes for Biomedical Research Horsham Research Centre Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom;
Novartis Institutes for Biomedical Research Horsham Research Centre Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom;
Novartis Institutes for Biomedical Research Horsham Research Centre Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom;
Novartis Institutes for Biomedical Research Horsham Research Centre Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom;
Novartis Institutes for Biomedical Research Horsham Research Centre Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom;
Novartis Institutes for Biomedical Research Horsham Research Centre Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom;
Novartis Institutes for Biomedical Research Horsham Research Centre Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom;
Novartis Institutes for Biomedical Research Horsham Research Centre Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom;
Novartis Institutes for Biomedical Research Horsham Research Centre Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom;
Novartis Institutes for Biomedical Research Horsham Research Centre Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom;
Novartis Institutes for Biomedical Research Horsham Research Centre Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom;
Novartis Institutes for Biomedical Research Horsham Research Centre Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom;
Novartis Institutes for Biomedical Research Horsham Research Centre Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom;
Novartis Institutes for Biomedical Research Horsham Research Centre Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom;
Novartis Institutes for Biomedical Research Horsham Research Centre Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom;
Novartis Institutes for Biomedical Research Horsham Research Centre Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom;
Novartis Institutes for Biomedical Research Horsham Research Centre Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom;
Novartis Institutes for Biomedical Research Horsham Research Centre Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom;
clinical candidate; DPlt; subgt; 2lt; /subgt; receptor antagonist; severe asthma;
机译:校正“Fevipiprant(NVP-QAW039)的发现,有效和选择性DP 2 sub>受体拮抗剂用于治疗哮喘”
机译:Fevipiprant,一种有效的选择性前列腺素D2受体2(DP2)拮抗剂,剂量依赖性地抑制哮喘小鼠模型中的肺炎症
机译:发现有效,选择性和口服可生物利用的炔基苯氧基乙酸CRTH2(DP2)受体拮抗剂,用于治疗过敏性炎症疾病
机译:有效和选择性肽激动剂/拮抗剂类似物在人黑色主义素受体-4
机译:在吸入性糖皮质激素治疗中,将白三烯受体拮抗剂与长效β激动剂相比,用于老年人的哮喘治疗:有效性,安全性和成本的回顾性数据分析。
机译:更正为发现夫芬普兰(NVP-QAW039)高效选择性的DP2受体拮抗剂治疗哮喘
机译:发现氟维西平(NVP-QAW039),一种有效的选择性DP2受体拮抗剂,可治疗哮喘